Stockscreener 앱 받기
20.22
0.80%
0.16
시장 영업 전:
20.29
0.07
+0.35%
전일 마감가:
$20.06
열려 있는:
$20.13
하루 거래량:
9.54M
Relative Volume:
0.87
시가총액:
$1.98B
수익:
$2.23B
순이익/손실:
$-248.39M
주가수익비율:
-7.5167
EPS:
-2.69
순현금흐름:
$-697.55M
1주 성능:
-7.29%
1개월 성능:
+48.51%
6개월 성능:
-80.97%
1년 성능:
-85.70%
1일 변동 폭
$19.41
$20.25
1주일 범위
$18.52
$22.05
52주 변동 폭
$10.41
$143.49
사렙타 테라퓨틱스 Stock (SRPT) Company Profile
명칭
Sarepta Therapeutics Inc
전화
617-274-4000
주소
215 FIRST STREET, CAMBRIDGE, MA
SRPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
20.22 | 2.05B | 2.23B | -248.39M | -697.55M | -2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
사렙타 테라퓨틱스 Stock (SRPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-29 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-07-29 | 개시 | Bernstein | Mkt Perform |
| 2025-07-29 | 재확인 | H.C. Wainwright | Sell |
| 2025-07-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2025-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-07-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-07-25 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-07-24 | 개시 | Citigroup | Sell |
| 2025-07-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-07-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-07-21 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-07-21 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2025-07-21 | 다운그레이드 | Needham | Hold → Underperform |
| 2025-07-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-18 | 다운그레이드 | Needham | Buy → Hold |
| 2025-06-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-06-17 | 개시 | Wolfe Research | Peer Perform |
| 2025-06-16 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-06-16 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | 다운그레이드 | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-11 | 개시 | Wells Fargo | Overweight |
| 2025-04-02 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-11-27 | 재확인 | Needham | Buy |
| 2024-11-25 | 개시 | H.C. Wainwright | Sell |
| 2024-11-07 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-07-29 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-05-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Outperform |
| 2023-12-13 | 재개 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-21 | 개시 | Wedbush | Outperform |
| 2023-10-31 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-04 | 개시 | Citigroup | Buy |
| 2023-03-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 재확인 | BTIG Research | Buy |
| 2022-12-16 | 업그레이드 | UBS | Neutral → Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 재확인 | Needham | Buy |
| 2021-12-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-08-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-01-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 개시 | Mizuho | Buy |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-08-21 | 재확인 | Needham | Buy |
| 2019-07-09 | 재확인 | Morgan Stanley | Overweight |
| 2019-07-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-11 | 재확인 | Credit Suisse | Outperform |
| 2018-10-12 | 개시 | Bernstein | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 재확인 | RBC Capital Mkts | Outperform |
| 2018-09-14 | 재개 | BofA/Merrill | Buy |
| 2018-09-06 | 개시 | Credit Suisse | Outperform |
| 2018-08-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 재확인 | Robert W. Baird | Outperform |
| 2018-06-20 | 재확인 | Needham | Buy |
| 2018-06-19 | 재확인 | H.C. Wainwright | Buy |
모두보기
사렙타 테라퓨틱스 주식(SRPT)의 최신 뉴스
Jim Cramer on Sarepta Therapeutics: "If it Goes Up, You Gotta Do Some Selling" - Yahoo Finance
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
2025-08-20 | Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Contact Levi & Korsinsky Before August 25, 2025 to Join Class Action | NDAQ:SRPT | Press Release - Stockhouse
SRPT Investors Have the Opportunity to Lead the Sarepta - GlobeNewswire
SRPT Investors Have the Opportunity to Lead the Sarepta Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - Morningstar
BofA Securities Adjusts Price Target on Sarepta Therapeutics to $17 From $10, Maintains Underperform Rating - MarketScreener
What MACD and RSI say about Sarepta Therapeutics Inc.Profit Target & Risk Controlled Swing Alerts - Newser
Will Sarepta Therapeutics Inc. bounce back from current supportWeekly Risk Summary & Fast Exit/Entry Strategy Plans - Newser
Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - news.stocktradersdaily.com
Sarepta Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Sarepta Therapeutics, Inc. (SRPT) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of August 25, 2025 Deadline - Barchart.com
Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky - GlobeNewswire
Earnings visualization tools for Sarepta Therapeutics Inc.2025 EndofYear Setup & Intraday High Probability Alerts - Newser
Burned by Sarepta Therapeutics, Inc.? Contact Levi & Korsinsky to SueWallSt and Fight Back - ACCESS Newswire
SRPT’s Stock Dilemma: Sarepta Therapeutics Inc’s Market Performance and Outlook - investchronicle.com
Shareholders that lost money on Sarepta Therapeutics, Inc.(SRPT) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - Morningstar
SRPT SECURITIES: Sarepta Therapeutics, Inc. Shareholders - GlobeNewswire
Sarepta Therapeutics, Inc. $SRPT Shares Sold by Maryland State Retirement & Pension System - Defense World
PNC Financial Services Group Inc. Has $149,000 Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - Defense World
Sarepta Therapeutics Inc. stock daily chart insightsJuly 2025 Trade Ideas & Safe Swing Trade Setup Alerts - Newser
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Over Securities ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Robbins LLP Reminds Sarepta Therapeutics, Inc. Stockholders - GlobeNewswire
Contact The Gross Law Firm by August 25, 2025 Deadline to - GlobeNewswire
Arrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue - Yahoo Finance
Sarepta Therapeutics (SRPT) August 25, 2025 Lead Plaintiff - GlobeNewswire
Investors in Sarepta Therapeutics, Inc. (SRPT): Protect Your RightsContact Levi & Korsinsky Before August 25, 2025 - Newsfile
Investors In Sarepta Therapeutics, Inc. (SRPT): Protect Your RightsContact Levi & Korsinsky Before August 25, 2025 - Barchart.com
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc.(SRPT) Shareholders - Morningstar
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
SRPT LOSSES: Sarepta Therapeutics, Inc. Investors with Losses are Encouraged to Contact BFA Law before Expiration of August 25 Class Action Deadline - Newsfile
How the Moms and Dads of Patients Won Sarepta’s Drug a Reprieve - Bloomberg.com
SRPT INVESTOR NOTICE: Robbins Geller Ruman & Dowd LLP - GlobeNewswire
Will Sarepta Therapeutics Inc. outperform the marketPortfolio Update Summary & Pattern Based Trade Signal System - Newser
Sarepta Therapeutics, Inc. $SRPT Shares Sold by LPL Financial LLC - Defense World
SRPT LOSS ALERT: Sarepta Therapeutics, Inc. Investors with - GlobeNewswire
SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities LawsuitContact the DJS Law Group Before the Final DeadlineSRPT - MarketScreener
How Sarepta Therapeutics Inc. (SRPT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
2025-08-17 | Securities Class Action Lawsuit Filed Against Sarepta Therapeutics, Inc. (SRPT)Levi & Korsinsky Represents Shareholders | NDAQ:SRPT | Press Release - Stockhouse
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSRPT - FinancialContent
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says - Defense World
Sarepta Changes Course, Agrees to Pause Elevidys Shipments - MSN
SRPT IMPORTANT DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, - GlobeNewswire
Sarepta Therapeutics and the Biotech Litigation Landscape: Navigating Risk in a High-Stakes Sector - AInvest
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - GlobeNewswire
SAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire
BFA Law Notifies SAREPTA THERAPEUTICS, INC. (SRPT) Investors to Contact the Firm before the Upcoming August 25 Securities Fraud Class Action Deadline - Newsfile
US Bancorp DE Decreases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
SRPT FRAUD REMINDER: Sarepta Therapeutics, Inc. Stock Drop - GlobeNewswire
Sarepta Therapeutics Faces Questions Over Its Key Gene Therapy - Finimize
사렙타 테라퓨틱스 (SRPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
사렙타 테라퓨틱스 주식 (SRPT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Barry Richard | Director |
May 16 '25 |
Option Exercise |
32.63 |
12,350 |
402,981 |
2,966,667 |
| Barry Richard | Director |
May 13 '25 |
Option Exercise |
19.23 |
20,246 |
389,359 |
2,954,317 |
| Nicaise Claude | Director |
Mar 12 '25 |
Option Exercise |
25.18 |
9,746 |
245,404 |
30,303 |
| Nicaise Claude | Director |
Mar 12 '25 |
Sale |
99.64 |
2,491 |
248,203 |
27,812 |
0.94%
1.72%
자본화:
|
볼륨(24시간):